NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Stock |
|||
NATSARS(COV2)-ST | Zeptometrix | Stock | 935 EUR |
SARS Spike Peptide |
|||
3219P | ProSci | 0.05 mg | 197.7 EUR |
Description: (NT) SARS Spike peptide |
|||
SARS Spike Peptide |
|||
3525P | ProSci | 0.05 mg | 197.7 EUR |
Description: (CT) SARS Spike peptide |
|||
SARS-E2 Antibody |
|||
abx016055-100ul | Abbexa | 100 ul | 493.2 EUR |
anti- SARS antibody |
|||
FNab07609 | FN Test | 100µg | 658.5 EUR |
Description: Antibody raised against SARS |
|||
SARS Spike Antibody |
|||
24216-100ul | SAB | 100ul | 468 EUR |
SARS Spike Antibody |
|||
24217-100ul | SAB | 100ul | 468 EUR |
SARS Spike Antibody |
|||
24218-100ul | SAB | 100ul | 468 EUR |
SARS Spike Antibody |
|||
24219-100ul | SAB | 100ul | 468 EUR |
SARS Spike Antibody |
|||
24318-100ul | SAB | 100ul | 468 EUR |
SARS Matrix Peptide |
|||
3527P | ProSci | 0.05 mg | 197.7 EUR |
Description: (NT) SARS Matrix peptide |
|||
SARS Matrix Peptide |
|||
3529P | ProSci | 0.05 mg | 197.7 EUR |
Description: (CT) SARS Matrix peptide |
|||
SARS Spike Antibody |
|||
20-abx137184 | Abbexa |
|
|
SARS Spike Antibody |
|||
20-abx137200 | Abbexa |
|
|
SARS Matrix Antibody |
|||
24319-100ul | SAB | 100ul | 468 EUR |
SARS Matrix Antibody |
|||
24320-100ul | SAB | 100ul | 468 EUR |
SARS cloning plasmid |
|||
CSB-CL020709HU1-10ug | Cusabio | 10ug | 451.2 EUR |
Description: A cloning plasmid for the SARS gene. |
|||
SARS cloning plasmid |
|||
CSB-CL020709HU2-10ug | Cusabio | 10ug | 451.2 EUR |
Description: A cloning plasmid for the SARS gene. |
|||
SARS Envelope Peptide |
|||
3531P | ProSci | 0.05 mg | 197.7 EUR |
Description: (NT) SARS Envelope peptide |
|||
SARS Envelope Peptide |
|||
3533P | ProSci | 0.05 mg | 197.7 EUR |
Description: (CT) SARS Envelope peptide |
|||
SARS Blocking Peptide |
|||
33R-7048 | Fitzgerald | 100 ug | 216 EUR |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SARS antibody, catalog no. 70R-1444 |
|||
SARS Blocking Peptide |
|||
33R-8713 | Fitzgerald | 100 ug | 216 EUR |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SARS antibody, catalog no. 70R-1445 |
|||
SARS Envelope Antibody |
|||
24321-100ul | SAB | 100ul | 468 EUR |
SARS Envelope Antibody |
|||
24322-100ul | SAB | 100ul | 468 EUR |
SARS Protease Substrate |
|||
H-5982.0500 | Bachem | 0.5mg | 356.4 EUR |
Description: Sum Formula: C66H119N21O22S; CAS# [587886-51-9] net |
|||
SARS Protease Substrate |
|||
H-5982.1000 | Bachem | 1.0mg | 618 EUR |
Description: Sum Formula: C66H119N21O22S; CAS# [587886-51-9] net |
|||
SARS Polyclonal Antibody |
|||
A53977 | EpiGentek |
|
|
SARS Polyclonal Antibody |
|||
A71293 | EpiGentek |
|
|
SARS Conjugated Antibody |
|||
C39139 | SAB | 100ul | 476.4 EUR |
Recombinant SARS SARS Mosaic S(C) Protein, Untagged, E.coli-1mg |
|||
QP13420-1mg | EnQuireBio | 1mg | 1273.2 EUR |
Recombinant SARS SARS Mosaic S(M) Protein, Untagged, E.coli-1mg |
|||
QP13421-1mg | EnQuireBio | 1mg | 1273.2 EUR |
Recombinant SARS SARS Mosaic S(N) Protein, Untagged, E.coli-1mg |
|||
QP13422-1mg | EnQuireBio | 1mg | 1273.2 EUR |
SARS Coronavirus antibody |
|||
10C-CR9003M1 | Fitzgerald | 100 ug | 598.8 EUR |
Description: Mouse monoclonal SARS Coronavirus antibody |
|||
Recombinant SARS SARS Mosaic S(C) Protein, Untagged, E.coli-100ug |
|||
QP13420-100ug | EnQuireBio | 100ug | 261.6 EUR |
Recombinant SARS SARS Mosaic S(C) Protein, Untagged, E.coli-500ug |
|||
QP13420-500ug | EnQuireBio | 500ug | 795.6 EUR |
Recombinant SARS SARS Mosaic S(M) Protein, Untagged, E.coli-100ug |
|||
QP13421-100ug | EnQuireBio | 100ug | 261.6 EUR |
Recombinant SARS SARS Mosaic S(M) Protein, Untagged, E.coli-500ug |
|||
QP13421-500ug | EnQuireBio | 500ug | 795.6 EUR |
Recombinant SARS SARS Mosaic S(N) Protein, Untagged, E.coli-100ug |
|||
QP13422-100ug | EnQuireBio | 100ug | 261.6 EUR |
Recombinant SARS SARS Mosaic S(N) Protein, Untagged, E.coli-500ug |
|||
QP13422-500ug | EnQuireBio | 500ug | 795.6 EUR |
SARS Nucleocapsid antibody |
|||
10R-10470 | Fitzgerald | 100 ug | 522 EUR |
Description: Mouse monoclonal SARS Nucleocapsid antibody |
|||
SARS Nucleocapsid antibody |
|||
10R-10471 | Fitzgerald | 100 ug | 522 EUR |
Description: Mouse monoclonal SARS Nucleocapsid antibody |
|||
SARS Nucleocapsid Antibody |
|||
20-abx137185 | Abbexa |
|
|
SARS Nucleocapsid Antibody |
|||
20-abx137201 | Abbexa |
|
|
SARS CoV E Protein |
|||
abx060650-1mg | Abbexa | 1 mg | 2030.4 EUR |
SARS protein (His tag) |
|||
80R-2099 | Fitzgerald | 50 ug | 386.4 EUR |
Description: Recombinant human SARS protein (His tag) |
|||
SARS ELISA KIT|Human |
|||
EF002719 | Lifescience Market | 96 Tests | 826.8 EUR |
Rat SARS shRNA Plasmid |
|||
20-abx988123 | Abbexa |
|
|
SARS (IN3) Spike Peptide |
|||
3225P | ProSci | 0.05 mg | 197.7 EUR |
Description: (IN) SARS (IN3) Spike peptide |
|||
SARS (IN1) Spike Peptide |
|||
3221P | ProSci | 0.05 mg | 197.7 EUR |
Description: (IN) SARS (IN1) Spike peptide |
|||
SARS (IN2) Spike Peptide |
|||
3223P | ProSci | 0.05 mg | 197.7 EUR |
Description: (IN) SARS (IN2) Spike peptide |
|||
SARS virus Sn Antibody |
|||
abx032683-400ul | Abbexa | 400 ul | 627.6 EUR |
SARS virus Sn Antibody |
|||
abx032683-80l | Abbexa | 80 µl | 343.2 EUR |
SARS virus Sm Antibody |
|||
abx032684-400ul | Abbexa | 400 ul | 627.6 EUR |
SARS virus Sm Antibody |
|||
abx032684-80l | Abbexa | 80 µl | 343.2 EUR |
Mouse SARS shRNA Plasmid |
|||
20-abx972567 | Abbexa |
|
|
SARS N Protein Antibody |
|||
abx018255-100ug | Abbexa | 100 ug | 460.8 EUR |
SARS N Protein Antibody |
|||
abx018256-100ug | Abbexa | 100 ug | 460.8 EUR |
SARS-CoV Spike Protein |
|||
abx060655-1mg | Abbexa | 1 mg | 2030.4 EUR |
Human SARS shRNA Plasmid |
|||
20-abx954245 | Abbexa |
|
|
PLPro Antibody (SARS-CoV) |
|||
100863 | BPS Bioscience | 250 µg | 360 EUR |
Description: Chicken polyclonal antibody recognizing the SARS-CoV Papain-like Protease (PLpro) as a 35 kDa protein. Purified from egg yolks. This antibody recognizes PLPro from both SARS-CoV-1 and SARS-CoV-2. Does not cross react with SARS-CoV 3CL protease. |
|||
SARS-CoV Spike Antibody |
|||
3225-002mg | ProSci | 0.02 mg | 206.18 EUR |
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
|||
SARS-CoV Spike Antibody |
|||
3225-01mg | ProSci | 0.1 mg | 523.7 EUR |
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
|||
SARS-CoV Spike Antibody |
|||
3219-002mg | ProSci | 0.02 mg | 206.18 EUR |
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
|||
SARS-CoV Spike Antibody |
|||
3219-01mg | ProSci | 0.1 mg | 523.7 EUR |
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
|||
SARS-CoV Spike Antibody |
|||
3221-002mg | ProSci | 0.02 mg | 206.18 EUR |
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
|||
SARS-CoV Spike Antibody |
|||
3221-01mg | ProSci | 0.1 mg | 523.7 EUR |
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
|||
SARS-CoV Spike Antibody |
|||
3223-002mg | ProSci | 0.02 mg | 206.18 EUR |
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
|||
SARS-CoV Spike Antibody |
|||
3223-01mg | ProSci | 0.1 mg | 523.7 EUR |
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
|||
SARS-CoV Matrix Antibody |
|||
3527-002mg | ProSci | 0.02 mg | 206.18 EUR |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
|||
SARS-CoV Matrix Antibody |
|||
3527-01mg | ProSci | 0.1 mg | 523.7 EUR |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
|||
SARS-CoV Matrix Antibody |
|||
3529-002mg | ProSci | 0.02 mg | 206.18 EUR |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2).The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
|||
SARS-CoV Matrix Antibody |
|||
3529-01mg | ProSci | 0.1 mg | 523.7 EUR |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2).The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
|||
SARS Protein Detection Set |
|||
PSI-1810 | ProSci | 1 Set | 884.4 EUR |
Description: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral S (Spike) protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. The M protein (Membrane protein, Matrix protein) is another major structural viral protein. It is an integral membrane protein involved in the budding of the viral particles and interacts with S protein and the nucleocapsid protein. The SARS E protein contains a short palindromic transmembrane helical hairpin that seems to deform lipid bilayers, which may explain its role in viral budding and virion envelope morphogenesis. ACE2, the SARS receptor, normally plays a central role in vascular, renal, and myocardial physiology. In contrast to its homolog ACE, ACE2 expression is restricted to heart, kidney, and testis.;;For images please see PDF data sheet |
|||
ACE2 (SARS Receptor) Antibody |
|||
abx032686-400ul | Abbexa | 400 ul | 627.6 EUR |
ACE2 (SARS Receptor) Antibody |
|||
abx032686-80l | Abbexa | 80 µl | 343.2 EUR |
SARS CoV-2 PCR kit |
|||
PCR-H731-48R | Bioingentech | 48T | 987.6 EUR |
SARS CoV-2 PCR kit |
|||
PCR-H731-96R | Bioingentech | 96T | 1335.6 EUR |
SARS-CoV Envelope Antibody |
|||
3533-002mg | ProSci | 0.02 mg | 206.18 EUR |
Description: SARS Envelope Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.Envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication. |
|||
SARS-CoV Envelope Antibody |
|||
3533-01mg | ProSci | 0.1 mg | 523.7 EUR |
Description: SARS Envelope Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.Envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication. |
|||
SARS Antibody, HRP conjugated |
|||
1-CSB-PA04145B0Rb | Cusabio |
|
|
Description: A polyclonal antibody against SARS. Recognizes SARS from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
|||
SARS Recombinant Protein (Rat) |
|||
RP227480 | ABM | 100 ug | Ask for price |
SARS CoV Nucleocapsid Protein |
|||
abx060652-1mg | Abbexa | 1 mg | 2247.6 EUR |
SARS Antibody, FITC conjugated |
|||
1-CSB-PA04145C0Rb | Cusabio |
|
|
Description: A polyclonal antibody against SARS. Recognizes SARS from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
|||
SARS Recombinant Protein (Mouse) |
|||
RP170009 | ABM | 100 ug | Ask for price |
SARS Recombinant Protein (Mouse) |
|||
RP170012 | ABM | 100 ug | Ask for price |
SARS Recombinant Protein (Human) |
|||
RP027604 | ABM | 100 ug | Ask for price |
SARS Recombinant Protein (Human) |
|||
RP027607 | ABM | 100 ug | Ask for price |
Polyclonal SARS Matrix Antibody |
|||
APR11178G | Leading Biology | 0.1 mg | 790.8 EUR |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human SARS Matrix . This antibody is tested and proven to work in the following applications: |
|||
Polyclonal SARS Matrix Antibody |
|||
APG02976G | Leading Biology | 0.1 mg | 790.8 EUR |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human SARS Matrix . This antibody is tested and proven to work in the following applications: |
|||
SARS-CoV Nucleocapsid Protein |
|||
abx060653-1mg | Abbexa | 1 mg | 2030.4 EUR |
SARS-CoV Nucleocapsid Protein |
|||
abx060654-1mg | Abbexa | 1 mg | 2030.4 EUR |
SARS Antibody, Biotin conjugated |
|||
1-CSB-PA04145D0Rb | Cusabio |
|
|
Description: A polyclonal antibody against SARS. Recognizes SARS from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA |
|||
Recombinant SARS Matrix Protein |
|||
VAng-Lsx0059-inquire | Creative Biolabs | inquire | Ask for price |
Description: SARS Matrix, recombinant protein from E. coli. |
|||
Sars ORF Vector (Rat) (pORF) |
|||
ORF075828 | ABM | 1.0 ug DNA | 607.2 EUR |
NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Variant B.1.351 Stock (1mL) |
|||
NATSARS(COV2-SA)-ST | Zeptometrix | 1 mL | 980 EUR |
NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Variant B.1.1.7 Stock (1mL) |
|||
NATSARS(COV2-UK)-ST | Zeptometrix | 1 mL | 980 EUR |
SARS ORF Vector (Human) (pORF) |
|||
ORF009202 | ABM | 1.0 ug DNA | 114 EUR |
SARS ORF Vector (Human) (pORF) |
|||
ORF009203 | ABM | 1.0 ug DNA | 114 EUR |
Sars ORF Vector (Mouse) (pORF) |
|||
ORF056671 | ABM | 1.0 ug DNA | 607.2 EUR |
Sars ORF Vector (Mouse) (pORF) |
|||
ORF056672 | ABM | 1.0 ug DNA | 607.2 EUR |
3CL Protease (SARS-CoV-2) |
|||
100823-1 | BPS Bioscience | 50 µg | 400 EUR |
Description: Severe acute respiratory Coronavirus 2 3C-like protease (SARS-CoV-2 3CL Protease), GenBank Accession No. YP_009725301, a.a. 1-306(full length), expressed in an E. coli expression system, MW=34 kDa. |
|||
3CL Protease (SARS-CoV-2) |
|||
100823-2 | BPS Bioscience | 500 µg_x000D_ | 3360 EUR |
Description: Severe acute respiratory Coronavirus 2 3C-like protease (SARS-CoV-2 3CL Protease), GenBank Accession No. YP_009725301, a.a. 1-306(full length), expressed in an E. coli expression system, MW=34 kDa. |
|||
SARS Nucleocapsid Recombinant Protein |
|||
10-213 | ProSci | 0.1 mL | 752.1 EUR |
Description: The nucleocapsid (N) protein of SARS-coronavirus (SARS-CoV) is the key protein for the formation of the helical nucleocapsid during virion assembly. The nucleocapsid (N) protein of SARS-CoV enters the host cell together with the viral RNA and interferes with several cellular processes. Some of these processes involve interactions between SARS-CoV N protein and host- cell proteins. It has also been demonstrated that the SARS-CoV N protein can bind to DNA in vitro. These interactions might have a role in the pathology of SARS. The N protein may be of potential value in vaccine development for specific prophylaxis and treatment against SARS. |
|||
SARS-CoV-2 Spike Peptide |
|||
9083P | ProSci | 0.05 mg | 235.5 EUR |
Description: (NT) SARS-CoV-2 Spike peptide |
|||
SARS-CoV-2 Spike Peptide |
|||
9087P | ProSci | 0.05 mg | 235.5 EUR |
Description: (CT) SARS-CoV-2 Spike RBD peptide |
|||
SARS-CoV-2 Spike Peptide |
|||
9091P | ProSci | 0.05 mg | 235.5 EUR |
Description: (IN) SARS-CoV-2 Spike peptide |
|||
SARS-CoV-2 Spike Peptide |
|||
9095P | ProSci | 0.05 mg | 235.5 EUR |
Description: (IN) SARS-CoV-2 Spike peptide |
|||
SARS-CoV-2 Antibody (ORF8) |
|||
RQ6296 | NSJ Bioreagents | 100 ug | 390.15 EUR |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined.~ ORF8 encodes a viral accessory protein. |
|||
SARS-CoV-2 Antibody (NSP2) |
|||
RQ6299 | NSJ Bioreagents | 100 ug | 390.15 EUR |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined.~ ORF1ab, the largest gene, contains overlapping open reading frames that encode polyproteins PP1ab and PP1a. The polyproteins are cleaved to yield 16 nonstructural proteins, NSP1-16. Production of the longer (PP1ab) or shorter protein (PP1a) depends on a -1 ribosomal frameshifting event. The proteins, based on similarity to other coronaviruses, include the papain-like proteinase protein (NSP3), 3C-like proteinase (NSP5), RNA-dependent RNA polymerase (NSP12, RdRp), helicase (NSP13, HEL), endoRNAse (NSP15), 2'-O-Ribose-Methyltransferase (NSP16) and other nonstructural proteins. SARS-CoV-2 nonstructural proteins are responsible for viral transcription, replication, proteolytic processing, suppression of host immune responses and suppression of host gene expression. The RNA-dependent RNA polymerase is a target of antiviral therapies. |
|||
SARS-CoV-2 Antibody (NSP3) |
|||
RQ6300 | NSJ Bioreagents | 100 ug | 390.15 EUR |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined. ORF1ab, the largest gene, contains overlapping open reading frames that encode polyproteins PP1ab and PP1a. The polyproteins are cleaved to yield 16 nonstructural proteins, NSP1-16. Production of the longer (PP1ab) or shorter protein (PP1a) depends on a -1 ribosomal frameshifting event. The proteins, based on similarity to other coronaviruses, include the papain-like proteinase protein (NSP3), 3C-like proteinase (NSP5), RNA-dependent RNA polymerase (NSP12, RdRp), helicase (NSP13, HEL), endoRNAse (NSP15), 2'-O-Ribose-Methyltransferase (NSP16) and other nonstructural proteins. SARS-CoV-2 nonstructural proteins are responsible for viral transcription, replication, proteolytic processing, suppression of host immune responses and suppression of host gene expression. The RNA-dependent RNA polymerase is a target of antiviral therapies. |
|||
SARS-CoV-2 Antibody (NSP4) |
|||
RQ6301 | NSJ Bioreagents | 100 ug | 390.15 EUR |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined.~ ORF1ab, the largest gene, contains overlapping open reading frames that encode polyproteins PP1ab and PP1a. The polyproteins are cleaved to yield 16 nonstructural proteins, NSP1-16. Production of the longer (PP1ab) or shorter protein (PP1a) depends on a -1 ribosomal frameshifting event. The proteins, based on similarity to other coronaviruses, include the papain-like proteinase protein (NSP3), 3C-like proteinase (NSP5), RNA-dependent RNA polymerase (NSP12, RdRp), helicase (NSP13, HEL), endoRNAse (NSP15), 2'-O-Ribose-Methyltransferase (NSP16) and other nonstructural proteins. SARS-CoV-2 nonstructural proteins are responsible for viral transcription, replication, proteolytic processing, suppression of host immune responses and suppression of host gene expression. The RNA-dependent RNA polymerase is a target of antiviral therapies. |
|||
SARS-CoV-2 Antibody (NSP7) |
|||
RQ6302 | NSJ Bioreagents | 100 ug | 390.15 EUR |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined.~ ORF1ab, the largest gene, contains overlapping open reading frames that encode polyproteins PP1ab and PP1a. The polyproteins are cleaved to yield 16 nonstructural proteins, NSP1-16. Production of the longer (PP1ab) or shorter protein (PP1a) depends on a -1 ribosomal frameshifting event. The proteins, based on similarity to other coronaviruses, include the papain-like proteinase protein (NSP3), 3C-like proteinase (NSP5), RNA-dependent RNA polymerase (NSP12, RdRp), helicase (NSP13, HEL), endoRNAse (NSP15), 2'-O-Ribose-Methyltransferase (NSP16) and other nonstructural proteins. SARS-CoV-2 nonstructural proteins are responsible for viral transcription, replication, proteolytic processing, suppression of host immune responses and suppression of host gene expression. The RNA-dependent RNA polymerase is a target of antiviral therapies. |
|||
SARS-CoV-2 Antibody (NSP8) |
|||
RQ6303 | NSJ Bioreagents | 100 ug | 390.15 EUR |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined.~ ORF1ab, the largest gene, contains overlapping open reading frames that encode polyproteins PP1ab and PP1a. The polyproteins are cleaved to yield 16 nonstructural proteins, NSP1-16. Production of the longer (PP1ab) or shorter protein (PP1a) depends on a -1 ribosomal frameshifting event. The proteins, based on similarity to other coronaviruses, include the papain-like proteinase protein (NSP3), 3C-like proteinase (NSP5), RNA-dependent RNA polymerase (NSP12, RdRp), helicase (NSP13, HEL), endoRNAse (NSP15), 2'-O-Ribose-Methyltransferase (NSP16) and other nonstructural proteins. SARS-CoV-2 nonstructural proteins are responsible for viral transcription, replication, proteolytic processing, suppression of host immune responses and suppression of host gene expression. The RNA-dependent RNA polymerase is a target of antiviral therapies. |
|||
SARS-CoV-2 Antibody (NSP9) |
|||
RQ6304 | NSJ Bioreagents | 100 ug | 390.15 EUR |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined.~ ORF1ab, the largest gene, contains overlapping open reading frames that encode polyproteins PP1ab and PP1a. The polyproteins are cleaved to yield 16 nonstructural proteins, NSP1-16. Production of the longer (PP1ab) or shorter protein (PP1a) depends on a -1 ribosomal frameshifting event. The proteins, based on similarity to other coronaviruses, include the papain-like proteinase protein (NSP3), 3C-like proteinase (NSP5), RNA-dependent RNA polymerase (NSP12, RdRp), helicase (NSP13, HEL), endoRNAse (NSP15), 2'-O-Ribose-Methyltransferase (NSP16) and other nonstructural proteins. SARS-CoV-2 nonstructural proteins are responsible for viral transcription, replication, proteolytic processing, suppression of host immune responses and suppression of host gene expression. The RNA-dependent RNA polymerase is a target of antiviral therapies. |
|||
QPCR Kit RNA SARS coronavirus |
|||
MOL8532 | Scientific Laboratory Supplies | EACH | 788.88 EUR |
QPCR Kit RNA SARS coronavirus |
|||
MOL8534 | Scientific Laboratory Supplies | EACH | 1010.04 EUR |
SARS-CoV-2 Antibody (ORF3a) |
|||
RQ6295 | NSJ Bioreagents | 100 ug | 390.15 EUR |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined. ORF3a encodes a viral accessory protein. Based on its similarity to other coronavirus proteins, ORF3a protein is thought to be a protein with ion channel activity (viroporin) that activates the NLRP3 inflammasome. ORF3a may also play a role in virus replication and pathogenesis. |
|||
SARS-CoV-2 Antibody (NSP10) |
|||
RQ6305 | NSJ Bioreagents | 100 ug | 390.15 EUR |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined.~ ORF1ab, the largest gene, contains overlapping open reading frames that encode polyproteins PP1ab and PP1a. The polyproteins are cleaved to yield 16 nonstructural proteins, NSP1-16. Production of the longer (PP1ab) or shorter protein (PP1a) depends on a -1 ribosomal frameshifting event. The proteins, based on similarity to other coronaviruses, include the papain-like proteinase protein (NSP3), 3C-like proteinase (NSP5), RNA-dependent RNA polymerase (NSP12, RdRp), helicase (NSP13, HEL), endoRNAse (NSP15), 2'-O-Ribose-Methyltransferase (NSP16) and other nonstructural proteins. SARS-CoV-2 nonstructural proteins are responsible for viral transcription, replication, proteolytic processing, suppression of host immune responses and suppression of host gene expression. The RNA-dependent RNA polymerase is a target of antiviral therapies. |
|||
SARS CoV-2 RT PCR kit |
|||
RTq-H731-100R | Bioingentech | 100T | 1573.2 EUR |
SARS CoV-2 RT PCR kit |
|||
RTq-H731-150R | Bioingentech | 150T | 2144.4 EUR |
SARS CoV-2 RT PCR kit |
|||
RTq-H731-50R | Bioingentech | 50T | 1155.6 EUR |
SARS Coronavirus IgG ELISA Kit |
|||
DEIA1035 | Creative Diagnostics | 96T | 2590.8 EUR |
Description: For the qualitative determination of IgG class antibodies against SARS Coronavirus in Human serum or plasma. It is intended for diagnosing and monitoring of patients related to infection by SARS Coronavirus. |